The Drugs Controller General of India (DCGI) has recommended that Serum Institute of India’s Covid vaccine Covovax be approved for use as a heterologous booster dose for those who have already received two doses of Covishield or Covaxin.
Previously, DCGI approved Covovax for restricted use in emergency situations in adults on December 28, 2021, for children aged 12 to 17 on March 9, 2022, and for children aged 7 to 11 on June 28, 2022, subject to certain conditions. Covovax is made possible by a technology transfer from Novavax. It has received conditional marketing authorization from the European Medicines Agency.
On December 17, 2021, the World Health Organization (WHO) granted it an emergency-use listing.
The Government of India recently approved Bharat Biotech’s nasal Covid vaccine for adults over the age of 18 for use as a heterologous booster dose.
Private hospitals will be able to obtain the vaccine.
Explore the profound effects of excessive screen time on your child’s behavior and development. Discover…
Discover how simple daily changes in your diet and lifestyle can significantly improve your heart…
This article explores the common misconception that brain tumours primarily affect older adults, revealing the…
The first-ever ovarian cancer vaccine is poised to change the landscape of women's health by…
As dengue and chikungunya cases rise in Delhi during the monsoon season, understanding prevention strategies…
Skincare is a significant concern for women (and increasingly, men), with the quest for perfect,…